Masaki Shiota

Kyushu University

Japan

Research Interests

Explore related searches

Professors in Japan Professors in Cancer Biology Cancer Biology professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

Jun Haginaka

JAPAN

View details

Norihiko Tsuchiya

Yamagata University

JAPAN

View details

Hideyasu Matsuyama

JAPAN

View details

Shuichi Tatarano

Associate professor/MD, PhD

Kagoshima University

JAPAN

View details

Taketo Kawai

Teikyo University School of Medicine

JAPAN

View details

Satoshi Kobayashi

Assistant Professor

Kyushu University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Masaki Shiota

Research Interests

Explore related searches

Contact this professor

Articles (30)

Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study

GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab

ASO Author Reflections: Predictive Factor for Contralateral Lymph Node Involvement in Clinically Unilateral Prostate Cancer

Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C‐CAT Database

Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM-Japan MONSTAR-SCREEN: a nationwide genomic profiling project

Prediction of Contralateral Lymph Node Involvement during Extended Pelvic Lymph Node Dissection for Clinically Unilateral Prostate Cancer

Active Surveillance in Prostate Cancer With Intermediate‐Risk Features: The PRIAS‐JAPAN Study

Risk Model for Lymph Node‐Positive Prostate Cancer After Radical Prostatectomy

Complete response to pembrolizumab in mismatch repair-deficient urothelial carcinoma with local recurrence and recurrent upper tract urothelial carcinoma: a case report

Editorial Comment

Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study

Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients

Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement

Reply to Letter to the Editor on “Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients”

Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis

Independent validation of genetic risk model to progression after intravesical bacillus Calmette‐Guérin therapy for non‐muscle invasive bladder cancer

Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study

Survival beyond cabazitaxel for metastatic castration‐resistant prostate cancer

ASO Author Reflections: Treatment Choice for Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study

Adverse events of cabozantinib plus nivolumab versus ipilimumab plus nivolumab

Clinical factors for tumor response, progression, and survival in nivolumab for advanced renal cell carcinoma in the SNiP‐RCC study

NR5A2/HSD3B1 pathway promotes cellular resistance to second-generation antiandrogen darolutamide

Differential cancer‐specific survival with curative radiotherapy to the prostate for metastatic prostate cancer according to estimated survival by risk group

Bone‐modifying agents are protective for symptomatic skeletal events in Radium‐223 treatment

Adverse Events of Abiraterone Acetate vs Enzalutamide

Fusion‐targeted biopsy significantly improves prostate cancer detection in biopsy‐naïve men

Steroidogenesis in castration-resistant prostate cancer

A Phase II Trial of Abiraterone With Dutasteride for Second‐Generation Antiandrogen‐ and Chemotherapy‐Naïve Patients With Castration‐Resistant Prostate Cancer

Collaborators (6)

Jun Haginaka

Norihiko Tsuchiya

Hideyasu Matsuyama

Shuichi Tatarano

Taketo Kawai

Satoshi Kobayashi

Make your next move.